GlassScriptPhysician profile
Jenelle Foote
NPI 1154329613
$11,140.88
in general payments reported to CMS, 2019-2025
31 companies · $603 in 2025
The $603 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $587 · 2020: $4,140 · 2021: $1,896 · 2022: $1,087 · 2023: $2,319 · 2024: $509 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,744 · Travel and Lodging: $1,619 · Education: $68.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,743.53 |
| Travel and Lodging | $1,618.77 |
| Education | $68.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $3,555.95 | 2019-2020 | |
| Axonics, INC. | $2,264.09 | 2020-2024 | Axonics, Bulkamid |
| Medtronic, INC. | $1,771.55 | 2021-2025 | Interstim, Altaviva |
| Boston Scientific Corporation | $874.10 | 2019-2025 | General - Erectile Dysfunction, Ams 700, Axonics |
| Astellas Pharma US INC | $669.22 | 2019-2025 | Xtandi, Veozah |
| Blue Earth Diagnostics | $423.79 | 2020-2024 | |
| Myriad Genetic Laboratories, INC. | $205.87 | 2020-2025 | Myrisk |
| Abbvie INC. | $193.59 | 2019-2023 | |
| Endo Pharmaceuticals INC. | $127.07 | 2020-2022 | |
| Sumitomo Pharma America, INC. | $110.41 | 2023-2025 | Orgovyx, Gemtesa |
| Photocure INC | $97.52 | 2019 | |
| Janssen Biotech, INC. | $90.97 | 2019-2024 | Erleada |
| Verity Pharmaceuticals INC. | $90.28 | 2023-2025 | Trelstar |
| Myovant Sciences INC. | $89.88 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $80.44 | 2020-2023 | Lynparza |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rochester Medical Corporation | $70.81 | 2021-2022 | |
| Dendreon Pharmaceuticals LLC | $66.17 | 2020 | |
| Coloplast Corp | $40.52 | 2019-2025 | |
| Procept Biorobotics Corporation | $39.74 | 2022-2023 | Aquabeam Robotic System |
| Pfizer INC. | $36.26 | 2019-2020 | |
| Angiodynamics, INC. | $31.37 | 2022 | |
| Acerus Pharmaceuticals Corporation | $30.08 | 2021 | |
| Valencia Technologies Corporation | $25.90 | 2023 | Ecoin Device Kit |
| Tolmar, INC. | $25.52 | 2023 | |
| Novartis Pharmaceuticals Corporation | $23.54 | 2019 | |
| Ferring Pharmaceuticals INC. | $23.46 | 2019 | |
| Abc Home Medical Supply, INC. | $21.65 | 2022 | |
| Glaxosmithkline, LLC. | $18.25 | 2025 | Benlysta |
| Clarus Therapeutics INC. | $16.78 | 2021 | |
| Metuchen Pharmaceuticals | $13.81 | 2019 | |
| Laborie Medical Technologies Corp. | $12.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenelle Foote listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.